AbbVie’s $906M Psychedelic Bet: What It Means for Psychedelic Medicine
The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest ...
The US pharmaceutical giant has put $906 million behind a next-generation psychedelic for depression, giving one of the industry’s largest ...
Emyria (ASX: EMD) has released its June 2026 quarterly update, highlighting strong revenue growth, national clinic expansion and encouraging early ...
Psychedelics.media delivers trusted news, intelligence, and insights for the global psychedelic medicine industry.
